Liddy James Gordon has made headlines with a recent filing detailing a significant stock option transaction involving Hepion Pharmaceuticals, Inc. The filing, submitted on October 27, 2026, reveals that Gordon acquired 510,000 stock options at an exercise price of $0.14 per share. This move underscores Gordon's confidence in Hepion's future prospects and may influence the company's strategic direction.

Background

Hepion Pharmaceuticals, Inc., a company incorporated in Delaware, operates within the pharmaceutical preparations sector. The company is known for its innovative approaches in the life sciences field. Hepion's recent filings indicate an active engagement in the market, with its fiscal year ending on December 31. The company has been listed under the Central Index Key (CIK) number 0001583771.

What the Filing Says

According to the filing (accession number 0001493152-26-048710), Gordon's stock option transaction occurred on October 23, 2026. The document states, "510,000 stock options were acquired, with an exercise price of $0.14 per share." Following this transaction, Gordon owns a total of 809,000 shares in Hepion Pharmaceuticals.

Impact

This transaction may have implications for various stakeholders, including investors, employees, and competitors within the pharmaceutical industry. As a director at Hepion, Gordon's actions could signal confidence in the company's growth and future initiatives. Such developments may also attract the attention of other industry players and investors looking to gauge Hepion's market position.

What's Next

The filing does not say what happens next.